{"id":"W2956067738","doi":"10.1158/1538-7445.am2019-ct073","title":"Abstract CT073: Pembrolizumab after two or more lines of prior therapy in patients with advanced small-cell lung cancer (SCLC): Results from the KEYNOTE-028 and KEYNOTE-158 studies","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Pembrolizumab; Medicine; Internal medicine; Response Evaluation Criteria in Solid Tumors; Clinical endpoint; Oncology; Progression-free survival; Lung cancer; Cancer; Phases of clinical research; Surrogate endpoint; Immunotherapy; Clinical trial; Surgery; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008914052,0.0004084299,0.0008817537,0.00028428,0.0001705095,0.00005125335,0.000443409,0.0001150597,0.0002782416],"category_scores_gemma":[0.0005225145,0.0002169147,0.00008407814,0.0008652536,0.0008135274,0.0002115829,0.0004342882,0.001075845,0.0000100021],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006625132,"about_ca_system_score_gemma":0.001196712,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.007784271,"about_ca_topic_score_gemma":0.006526816,"domain_scores_codex":[0.9955078,0.0002210642,0.00062996,0.0009566743,0.001674798,0.001009729],"domain_scores_gemma":[0.9955102,0.001468166,0.0002026647,0.0009699955,0.001643725,0.0002053032],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1165475,0.0004143734,0.8357564,0.001126599,0.000879927,0.00006986415,0.01218654,0.0001950366,0.00365253,0.000002011988,0.002274923,0.02689428],"study_design_scores_gemma":[0.03541546,0.001452706,0.9498686,0.002973914,0.00006162435,6.879661e-7,0.002250707,0.00006056673,0.00606384,0.00001758828,0.001525715,0.000308615],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.944636,0.04711782,4.866672e-7,0.003547478,0.0001751542,0.003811457,0.000458996,0.00002864231,0.0002240021],"genre_scores_gemma":[0.9623315,0.03433079,0.0001164759,0.000253435,0.0002900907,0.001035236,0.00002641305,0.00008472751,0.001531309],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1141121,"threshold_uncertainty_score":0.998823,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05775550792935844,"score_gpt":0.4330473040302196,"score_spread":0.3752917961008612,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}